Adaptive Biotechnologies Corp (ADPT)

Jan 14, 2025, 7:30 AM EST - 3 days ago

Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients

Jan 7, 2025, 7:30 AM EST - 10 days ago

Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025

Jan 2, 2025, 4:05 PM EST - 15 days ago

Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 11, 2024, 6:55 AM EST - 5 weeks ago

Top 3 Health Care Stocks That May Collapse This Quarter

FNA NAMS

Dec 7, 2024, 6:30 PM EST - 5 weeks ago

Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions

Dec 3, 2024, 7:30 AM EST - 6 weeks ago

Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting

Nov 26, 2024, 10:53 AM EST - 7 weeks ago

Adaptive Biotechnologies: Making Some Progress

Nov 7, 2024, 9:57 PM EST - 2 months ago

Adaptive Biotechnologies Corporation (ADPT) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 7:30 AM EST - 2 months ago

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma

Oct 9, 2024, 4:05 PM EDT - 3 months ago

Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024

Aug 29, 2024, 7:30 AM EDT - 5 months ago

Adaptive Announces IVDR Certification for clonoSEQ® in European Union

Aug 22, 2024, 4:03 PM EDT - 5 months ago

Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 1, 2024, 10:25 PM EDT - 6 months ago

Adaptive Biotechnologies Corporation (ADPT) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 4:05 PM EDT - 6 months ago

Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results

Jul 11, 2024, 4:05 PM EDT - 6 months ago

Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024

May 31, 2024, 7:30 AM EDT - 8 months ago

Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

May 29, 2024, 4:05 PM EDT - 8 months ago

Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 7, 2024, 8:59 PM EDT - 9 months ago

Adaptive Biotechnologies Corporation (ADPT) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:05 PM EDT - 9 months ago

Adaptive Biotechnologies Reports First Quarter 2024 Financial Results

Apr 17, 2024, 4:05 PM EDT - 9 months ago

Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024

Apr 2, 2024, 4:05 PM EDT - 10 months ago

Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue

Mar 27, 2024, 8:30 AM EDT - 10 months ago

Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024

Feb 22, 2024, 4:05 PM EST - 11 months ago

Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference

Feb 14, 2024, 9:51 PM EST - 1 year ago

Adaptive Biotechnologies Corporation (ADPT) Q4 2023 Earnings Call Transcript

ANY

Feb 14, 2024, 4:05 PM EST - 1 year ago

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results

Jan 29, 2024, 4:05 PM EST - 1 year ago

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024

Dec 27, 2023, 4:05 PM EST - 1 year ago

Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 9, 2023, 8:30 AM EST - 1 year ago

Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting

Dec 5, 2023, 7:30 AM EST - 1 year ago

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting

Nov 9, 2023, 10:01 PM EST - 1 year ago

Adaptive Biotechnologies Corporation (ADPT) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 5:52 PM EST - 1 year ago

Adaptive Biotech hires Goldman Sachs to explore ‘strategic alternatives' for key business lines

Nov 9, 2023, 4:05 PM EST - 1 year ago

Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 7, 2023, 7:30 AM EST - 1 year ago

Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene's Lymphoid Malignancy Pipeline

Nov 2, 2023, 4:05 PM EDT - 1 year ago

Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023

Sep 27, 2023, 5:05 PM EDT - 1 year ago

Adaptive Biotechnologies: Not Quite There Yet, Growth Looks Priced

Sep 13, 2023, 7:30 AM EDT - 1 year ago

Adaptive Announces Launch of Epic Integration for clonoSEQ®

Aug 30, 2023, 4:30 PM EDT - 1 year ago

Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Aug 2, 2023, 10:38 PM EDT - 1 year ago

Adaptive Biotechnologies Corporation (ADPT) Q2 2023 Earnings Call Transcript

Aug 2, 2023, 4:05 PM EDT - 1 year ago

Adaptive Biotechnologies Reports Second Quarter 2023 Financial Results

Jul 10, 2023, 4:05 PM EDT - 1 year ago

Adaptive Biotechnologies to Report Second Quarter Financial Results on August 2, 2023

Jul 7, 2023, 2:00 PM EDT - 1 year ago

Adaptive Biotechnologies: Getting Closer To The 'Buy Zone'

Jun 2, 2023, 7:34 AM EDT - 1 year ago

Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay's Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer

May 24, 2023, 4:05 PM EDT - 1 year ago

Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences

May 12, 2023, 8:00 AM EDT - 1 year ago

Adaptive Biotechnologies to Participate in the 2023 RBC Capital Markets Global Healthcare Conference

May 9, 2023, 7:30 AM EDT - 1 year ago

Adaptive Biotechnologies Announces FDA Acceptance of Genentech's Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology

May 3, 2023, 11:16 PM EDT - 1 year ago

Adaptive Biotechnologies Corporation (ADPT) Q1 2023 Earnings Call Transcript

May 3, 2023, 4:05 PM EDT - 1 year ago

Adaptive Biotechnologies Reports First Quarter 2023 Financial Results

Apr 25, 2023, 4:05 PM EDT - 1 year ago

Adaptive Biotechnologies to Participate in the BofA Securities 2023 Healthcare Conference

Apr 12, 2023, 7:30 AM EDT - 1 year ago

Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline

Apr 6, 2023, 4:05 PM EDT - 1 year ago

Adaptive Biotechnologies to Report First Quarter Financial Results on May 3, 2023